Navigation Links
Forest Laboratories, Inc. and Laboratorios Almirall, S.A. Provide an Update on the Aclidinium Bromide Clinical Development Program
Date:3/6/2009

options to improve lung function and control exacerbations.

About aclidinium bromide and Genuair(R)

Aclidinium bromide is a novel, long-acting inhaled anticholinergic bronchodilator which has a long residence time at the M3 receptors and a shorter residence time at the M2 receptors. Aclidinium is rapidly hydrolyzed in human plasma to two major inactive metabolites. Forest Laboratories licensed US rights for aclidinium from Almirall, while Almirall maintains rights for the rest of the world. The companies are jointly involved in the development of the compound.

Aclidinium bromide is administered to patients using a novel, state-of-the-art multidose dry powder inhaler (MDPI), Genuair(R)(2). Genuair(R) was designed with an intuitive feedback system, which through a 'colored control window' and an audible click indicates that the patient has inhaled correctly. The Genuair(R) inhaler contains multiple doses with a visible dose level indicator and also incorporates significant safety features such as an anti-double dosing mechanism and an end-of-dose lock-out system to prevent use of an empty inhaler.

About Forest Laboratories

Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people's lives. In addition to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest's current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The company is headquartered in New York, NY. To learn more about Forest Laboratories, visit www.FRX.com.

Except for the historical information co
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Forest Laboratories, Inc. and Cypress Bioscience, Inc. Announce Positive Results of Phase III Study of Milnacipran for the Management of Fibromyalgia
2. Ironwood and Forest Present Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
3. Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase II Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
4. Ironwood and Forest to Present Positive Data From Linaclotide Phase 2b IBS-C Study at ACG Annual Scientific Conference
5. Forest Laboratories Announces Positive Results from Phase III Clinical Studies of Ceftaroline for the Treatment of Complicated Skin and Skin Structure Infections
6. Ironwood Pharmaceuticals and Forest Laboratories Announce Presentation of Linaclotide Phase 2b Chronic Constipation Study Results
7. Forest and Almirall Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel, Long-Acting Anticholinergic for the Treatment for COPD
8. Microbia and Forest Laboratories Announce Preliminary Results of Linaclotide Phase 2b Studies
9. Forest Laboratories, Inc. Announces Positive Results of LEXAPRO(R) Phase III Study in Adolescents With Major Depression
10. Forest Laboratories, Inc. and Gedeon Richter Announce Results of Phase II-B Study for RGH-188 as a Treatment for Schizophrenia
11. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... 2014 Enable Injections , developer of ... it easy and nearly painless for patients to self-inject ... has been named winner of the ,Buzz of BIO ... biotech sector.    Enable is one of only ... number of votes in the "Late Stage Leaders" category.  ...
(Date:9/23/2014)... Sept. 23, 2014   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade hypothermic storage ... precision thermal shipping products for cells and tissues  ... to its Scientific Advisory Board.  The new members are ... , PhD. Dr. Acker is a Senior ...
(Date:9/23/2014)... LONDON , September 23, 2014 ... pharmaceutical assets, announces the appointment of Jarrod ... role, Mr Longcor is responsible for structuring, negotiating ... financial investments, as well as providing management and ... member of the Executive leadership team. ...
Breaking Medicine Technology:Innovative Wearable Injector Developer, Enable Injections, Wins 'Buzz of BIO Investor Forum' 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 2BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 3BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 4BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 5BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 6BioLife Solutions Announces the Addition of Jason Acker, MBA, PhD and Anthony Davies, PhD to its Scientific Advisory Board 7Avillion Appoints Jarrod Longcor as Chief Business Officer 2
... May 26, 2011 Rigel Pharmaceuticals, Inc. ... of its previously announced underwritten public offering of 16,300,000 ... of $8.00 per share to the public. The gross ... be approximately $130,400,000, before deducting underwriting discounts and commissions, ...
... Endo Pharmaceuticals Holdings Inc. (NASDAQ: ENDP ) ... amount of senior unsecured notes. The notes will be unsecured, ... certain of the Company,s subsidiaries.   Endo intends ... cash on hand and borrowings under its new credit facility, ...
Cached Medicine Technology:Rigel Announces Pricing of Public Offering of Common Stock 2Rigel Announces Pricing of Public Offering of Common Stock 3Endo Pharmaceuticals Holdings Inc. Announces Proposed Private Offering of Senior Notes 2
(Date:9/23/2014)... Wohl Associates of Bohemia, NY, specialists ... taken delivery of used industrial pasta machinery from Toresani ... equipment for producing gnocchi and tortelloni. , The mixers ... La Parmigiana mixer/extruder. With a 2.2 kW (5 HP) ... is 17” wide, 28” long and 23” deep that ...
(Date:9/23/2014)... OR (PRWEB) September 23, 2014 Humans do ... their waste water as they could says leading waste water ... Grigg advocated a program in which 100% of all water ... as pure as when it was removed. Solid waste removed ... to the environment. Grigg explained his Total Water Management (TWM) ...
(Date:9/23/2014)... Rosa, CA (PRWEB) September 23, 2014 On ... the arrival of the most technically advanced horticultural LED grow ... it again with the XL750 and XL1000 ... as well as the experienced horticulturalist, because it has what ... the light spectrum. Kind LED's grower-tested 12 band spectrum (also ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 A ... and Digestive and Kidney Diseases has found ... more cases of adults and children developing kidney stones. ... 2005 - 2011 across several U.S. cities, including Dallas, ... that patients usually sought treatment for kidney stones within ...
(Date:9/23/2014)... Hope For The Warriors® is excited ... be hosted in Boston, Massachusetts on Sunday, November 9, ... signature event honors the courage of our wounded service ... Proceeds from the evening will benefit Hope For The ... of self, restoring the family unit, and restoring hope ...
Breaking Medicine News(10 mins):Health News:Used Industrial Pasta Machinery Now Available at Wohl Associates 2Health News:Leading Water Treatment Expert Calls for 100% Waste Water Recycling 2Health News:Leading Water Treatment Expert Calls for 100% Waste Water Recycling 3Health News:Kind LED K5 Series XL1000 Grow Lights Sell Out in Only 2 Days 2Health News:New Study Finds Link Between Higher Temperatures and Kidney Stones in the United States 2Health News:New Study Finds Link Between Higher Temperatures and Kidney Stones in the United States 3Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 2Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 3
... so many problems in our health care delivery,system and ... are having problems getting care as well as paying ... Health & Science University,family physician. The study, "Insurance Plus ... Health Care Access for Low Income,Families," recently was published ...
... in the world over 300 families are being recruited ... the treatment of childhood eczema. , The independent trial ... received funding of nearly 1million from the Department of ... Assessment (HTA) programme. The study will focus on hard ...
... a CT scan, and the masses look benign, they ... recent study conducted by researchers at Brown University in ... CT, we are frequently encountering findings that are not ... called incidentalomas, of which adrenal masses are quite common, ...
... to Evaluate Ultra-Pure Ethyl EPA-Niacin ... Treatment of Niacin- Induced Flushing, LONDON, November 29 ... has commenced a phase I clinical,safety and efficacy trial in ... and niacin on niacin induced,flushing. Flushing is a common side ...
... 29 Diabetes Response,Service, the first and only ... and Canada December 1st, 2007 providing scheduled,daily phone ... subscribers to,prevent hypoglycemia and complications such as seizures, ... provides customizable,scheduled text message reminders to help manage ...
... Nov. 29 As part of its HIV,Testing ... for,leading experts on HIV/AIDS issues including HIV screening, ... women., In September 2006, Centers for Disease ... screening that called for,voluntary opt-out screening to be ...
Cached Medicine News:Health News:New study shows low-income families face 3 barriers to health care 2Health News:New study shows low-income families face 3 barriers to health care 3Health News:Eczema sufferers test out benefits of water softeners 2Health News:Eczema sufferers test out benefits of water softeners 3Health News:Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program 2Health News:Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program 3Health News:Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program 4Health News:Amarin Commences First Clinical Trial in Cardiovascular ProgramAmarin Commences First Clinical Trial in Cardiovascular Program 5Health News:Diabetes Response Service Launches in U.S. and Canada 2Health News:Experts Available to Discuss World AIDS Day, HIV/AIDS Issues Facing America 2
... ENA Multiparameter Kit is designed ... six of the most common ... unique quality control system. The ... well in each strip gives ...
Inquire...
Microalbumin Linearity Control...
The K-ASSAY Lp(a) Control Set is intended for use as an assayed quality control material for monitoring the performance of Lp(a) immunoturbidimetric assays....
Medicine Products: